ITEM 7.01 - Regulation FD Disclosure.

On February 3, 2020, Insmed Incorporated issued a press release announcing positive top-line results from its Phase 2 WILLOW study of INS1007 in patients with non-cystic fibrosis bronchiectasis. The press release is attached hereto as Exhibit 99.1 and incorporated in this Item 7.01 by reference.

The information contained in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01 - Financial Statements and Exhibits.





(d) Exhibits



Exhibit
No.                                     Description
  99.1       Press release issued by Insmed Incorporated on February 3, 2020.
104        Cover Page Interactive Data File (embedded within the Inline XBRL
           document).

© Edgar Online, source Glimpses